JBT Marel Corporation
JBTM
$116.86
+0.60%
JBT Marel Corporation is a global technology solutions provider serving the food and beverage industry, with two primary segments: Protein Solutions, which focuses on initial processing and harvesting of animal proteins (poultry, pork, fish, and beef), and Prepared Food and Beverage Solutions, which offers downstream value-added processing, preservation, and packaging solutions for ready-to-eat products, as well as capabilities in pet food, dairy, bakery, pharmaceutical, and warehouse automation. As a market leader in food processing equipment, JBT Marel is distinct for its comprehensive portfolio that spans from primary protein processing to final packaging, positioning it as a one-stop partner for food manufacturers. The current investor narrative centers on the company's integration and synergy realization following the Marel merger, with attention on margin expansion, cost synergies, and the potential for growth in automation and sustainable food processing solutions, despite recent stock price weakness and broader market volatility.…
JBTM
JBT Marel Corporation
$116.86
Investment Opinion: Should I buy JBTM Today?
Based on the analysis, I rate JBTM as a Buy, but with high risk. The consensus recommendation is 'buy' with an average target price of $176.42, implying a 50.9% upside. The thesis is that the market is overly pessimistic about the Marel integration, and the company's strong market position and low forward P/E of 12.64x offer an attractive risk-reward for patient investors.
Sign up to view all
JBTM 12-Month Price Forecast
The AI assessment is cautiously bullish, as the fundamental valuation metrics suggest the stock is undervalued relative to its forward earnings potential. The low forward P/E and strong analyst support indicate that the market may be overly pessimistic about the merger integration. However, the negative trailing earnings and high EV/EBITDA introduce significant uncertainty. The stance would be upgraded to strongly bullish if the company reports positive EPS and demonstrates clear synergy realization. Conversely, it would be downgraded to neutral or bearish if the company misses earnings estimates or the integration faces major setbacks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on JBT Marel Corporation's 12-month outlook, with a consensus price target around $176.42 and implied upside of +51.0% versus the current price.
Average Target
$176.42
0 analysts
Implied Upside
+51.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$118 - $210
Analyst target range
JBTM has coverage from 6 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.67 (where 1 is strong buy and 5 is sell). The average target price is $176.42, implying a substantial upside of 50.9% from the current price of $116.86. The target price range is from a low of $118.00 to a high of $210.00, with the low target near the current price, indicating some analysts see limited downside, while the high target suggests significant upside potential. The wide spread between the low and high targets (92 points) reflects high uncertainty about the company's future, likely due to the integration of Marel and the potential for either strong synergy realization or execution risks. The consensus leans bullish, but the low target near the current price indicates that not all analysts are convinced of a rapid recovery, and the stock's recent underperformance relative to the S&P 500 (relative strength of -36.89% over 1 year) suggests that the market is skeptical of the near-term outlook.
Bulls vs Bears: JBTM Investment Factors
JBTM presents a classic value-versus-value-trap debate. On the bull side, the stock offers a compelling forward P/E of 12.64x, a consensus Buy rating with 50.9% upside to the average target, and the potential for significant margin expansion from Marel synergies. On the bear side, the stock is in a steep downtrend, near its 52-week low, with negative trailing earnings, a high EV/EBITDA, and elevated short interest. The most critical tension is whether the merger integration will deliver the expected synergies and restore profitability. If it does, the stock is deeply undervalued; if not, the stock could continue to slide. Currently, the bearish technicals and negative sentiment outweigh the fundamental value, but the potential reward is substantial. The evidence slightly favors the bull case given the low forward multiple and analyst conviction, but the risk is high.
Bullish
- Analyst consensus is Buy with 50.9% upside: The average analyst target price is $176.42, implying a 50.9% upside from the current price of $116.86. The consensus recommendation is 'buy' with a mean score of 1.67, indicating strong bullish sentiment among the 6 covering analysts.
- Forward P/E of 12.64x is attractive: Despite negative trailing earnings, the forward P/E of 12.64x is low for an industrial machinery company, suggesting the market expects a significant earnings recovery. If the company achieves the estimated EPS of $11.25, the stock is trading at a discount to its growth potential.
- Merger synergies could drive margin expansion: The Marel merger is expected to generate cost synergies, which could improve the current operating margin of 4.99% and net margin of -1.33%. Successful integration could lead to substantial earnings growth, as reflected in the high EV/EBITDA of 31.6x, which implies market expectations of future EBITDA expansion.
- Strong market position in food processing: JBT Marel is a market leader in food processing equipment, with a comprehensive portfolio from primary protein processing to packaging. This positions the company to benefit from long-term trends in automation and sustainable food processing, providing a solid foundation for revenue growth.
Bearish
- Stock in steep downtrend, near 52-week low: JBTM is down 29.14% over the past six months and 16.41% over the past year, trading at $116.86, just 2.8% above its 52-week low of $113.67. The stock is in a pronounced downtrend, with relative strength of -36.89% vs. the S&P 500 over one year, indicating persistent underperformance.
- Negative net margin and EPS: The trailing twelve-month net margin is -1.33% with an EPS of -$0.0064, indicating the company is currently unprofitable. This is likely due to merger-related costs, but it raises concerns about the timeline to profitability and the risk of further dilution or cost overruns.
- Elevated EV/EBITDA of 31.6x: The EV/EBITDA ratio of 31.6x is high, suggesting the market is pricing in significant future EBITDA growth. If synergies fail to materialize or integration takes longer than expected, the stock could face multiple compression, leading to further downside.
- High short interest and low current ratio: The short ratio is 7.43, indicating a high level of short interest and bearish sentiment. Additionally, the current ratio of 0.98 suggests potential liquidity concerns, as current liabilities exceed current assets, which could strain operations if cash flow remains weak.
JBTM Technical Analysis
JBTM is currently in a pronounced downtrend, with the stock price at $116.86, down 16.41% over the past year and 29.14% over the past six months. The stock is trading near the lower end of its 52-week range, at approximately 68.7% of the range (calculated as (116.86 - 113.67) / (170.19 - 113.67)), indicating significant weakness and proximity to its 52-week low of $113.67. This positioning suggests the market is pricing in substantial negative sentiment, and the stock is either approaching a value opportunity or is in a falling knife scenario, depending on fundamental catalysts.
Beta
0.94
0.94x market volatility
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
$114-$170
Price range past year
Annual Return
-16.4%
Cumulative gain past year
| Period | JBTM Return | S&P 500 |
|---|---|---|
| 1m | -13.6% | +3.6% |
| 3m | -11.5% | +2.7% |
| 6m | -29.1% | +11.4% |
| 1y | -16.4% | +18.7% |
| ytd | -22.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JBTM Fundamental Analysis
JBTM's revenue trajectory is not directly provided in the data, but the company's estimated revenue for the next fiscal year is $4.47 billion, with a forward P/E of 12.64x, implying expected earnings growth. The most recent quarterly financials are not available, but the trailing twelve-month net margin is -1.33%, indicating the company is currently unprofitable, with a negative EPS of -$0.0064. The gross margin is 35.14%, which is typical for industrial machinery, but the operating margin is only 4.99%, suggesting significant operating expenses or integration costs from the Marel merger. The negative net margin and EPS indicate the company is in a transition phase, likely due to merger-related costs, and the path to profitability is a key focus for investors.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JBTM Overvalued?
Given that JBTM's trailing net income is negative (EPS of -$0.0064), the price-to-sales (PS) ratio is the primary valuation metric, currently at 2.06x. The forward P/E of 12.64x is positive, indicating the market expects profitability to return, and the gap between the negative trailing P/E and positive forward P/E suggests the market is pricing in a significant earnings recovery. The EV-to-EBITDA ratio is 31.60x, which is elevated, reflecting the market's expectation of future EBITDA growth. Compared to the industry average (not provided), JBTM's PS ratio of 2.06x is likely in line with or slightly above industrial machinery peers, but the forward P/E of 12.64x appears attractive if the company can achieve its earnings estimates. Historical valuation data is not available, but the current PS ratio is below the company's 52-week high price, suggesting the stock is trading at a discount to its recent valuation levels.
PE
-153.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company is currently unprofitable with a negative net margin of -1.33% and EPS of -$0.0064, indicating that merger-related costs are weighing on earnings. The operating margin is only 4.99%, suggesting high operating expenses or integration inefficiencies. The current ratio of 0.98 indicates that current liabilities exceed current assets, which could lead to liquidity stress if cash flow does not improve. Additionally, the debt-to-equity ratio of 0.42 is moderate, but the high EV/EBITDA of 31.6x implies that the market expects substantial EBITDA growth; if this fails to materialize, the stock could face de-rating. The negative payout ratio and dividend yield of 0.27% suggest that dividends are not well-covered, and the company may need to conserve cash for integration efforts.
FAQ
The key risks are: 1) Integration risk: The Marel merger may not deliver the expected synergies, leading to continued losses and margin pressure. The current net margin is -1.33%, and any further deterioration could hurt the stock. 2) Financial risk: The current ratio of 0.98 indicates potential liquidity issues, and the negative payout ratio suggests dividends are not well-covered. 3) Market risk: The stock has underperformed the S&P 500 by 36.89% over the past year, and high short interest (7.43) indicates bearish sentiment. 4) Valuation risk: The high EV/EBITDA of 31.6x leaves little room for error; if growth expectations are not met, the stock could de-rate significantly. The most severe risk is a combination of integration failure and market downturn, which could push the stock below $100.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $176-$210, driven by successful integration and strong earnings growth. Base case (45% probability) targets $150-$176, assuming gradual improvement and a return to profitability. Bear case (25% probability) targets $100-$118, if integration fails and losses persist. The most likely scenario is the base case, with the stock recovering to the average analyst target of $176.42, as the market begins to recognize the value of the merger. However, the wide range of analyst targets reflects high uncertainty, and the actual outcome will depend on the company's execution over the next few quarters.
Based on the forward P/E of 12.64x, JBTM appears undervalued relative to its expected earnings of $11.25 per share. The PS ratio of 2.06x is reasonable for an industrial machinery company, and the EV/EBITDA of 31.6x is high, but this reflects market expectations of future growth. Compared to its own history, the stock is trading near its 52-week low, suggesting a discount to recent valuation levels. The market is pricing in a significant earnings recovery, and if the company meets its estimates, the stock is undervalued. However, the negative trailing earnings and high EV/EBITDA indicate that the market is also pricing in execution risk. Overall, the valuation is attractive if the merger synergies are realized, but it is not a clear-cut bargain.
JBTM is a good buy for investors with a high risk tolerance and a long-term horizon, given the substantial upside to the average analyst target of $176.42 (50.9% upside) and the low forward P/E of 12.64x. However, the stock is near its 52-week low and has negative trailing earnings, so it is not without risk. The biggest downside risk is that the Marel integration fails to deliver expected synergies, leading to continued losses and further stock declines. For investors who believe in the merger thesis and can withstand volatility, the current price offers an attractive entry point. For conservative investors, it may be prudent to wait for evidence of profitability before buying.
JBTM is more suitable for long-term investment, as the merger integration and synergy realization are expected to take time. The stock is currently in a downtrend, and short-term traders may face high volatility and negative momentum. The beta of 0.94 suggests moderate market correlation, but the stock's recent underperformance indicates that it may not recover quickly. For long-term investors, the low forward P/E and potential for margin expansion offer a compelling opportunity, but they should be prepared to hold for at least 12-24 months to allow the integration to play out. The dividend yield is minimal (0.27%), so income is not a primary reason to hold. Given the high uncertainty, a minimum holding period of 18 months is recommended to ride out the volatility and capture the potential upside.